Synlogic Inc. (NASDAQ: SYBX)
$1.56
+0.0600 ( +4.00% ) 11.5K
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.
Market Data
Open
$1.56
Previous close
$1.50
Volume
11.5K
Market cap
$18.32M
Day range
$1.52 - $1.63
52 week range
$1.35 - $8.85
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Mar 19, 2024 |
8-k | 8K-related | 15 | Feb 22, 2024 |
8-k | 8K-related | 18 | Feb 20, 2024 |
3 | Insider transactions | 1 | Feb 16, 2024 |
8-k | 8K-related | 14 | Feb 12, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
8-k | 8K-related | 16 | Dec 29, 2023 |
8-k | 8K-related | 12 | Nov 17, 2023 |
8-k | 8K-related | 12 | Nov 15, 2023 |